Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Earnings Results, Misses Estimates By $0.14 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) posted its quarterly earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14), FiscalAI reports. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.23 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• Both Phase III wet AMD trials missed their primary endpoint in the full analysis population. EyePoint highlighted DURAVYU’s biological activity, reduced treatment burden, and safety, but is discontinuing the wet AMD program while it reviews whether any patient subgroup could support a future path.
• EyePoint ended September with about $118 million in cash and expects to fund operations into late Q3 2027, while COMO and CAPRI results are expected in early Q4 2027. Management says it is evaluating additional cost reductions, financing, and business-development options to preserve runway and reach the readouts.
• EyePoint is concentrating its clinical efforts on DME, citing the disease’s distinct biology and Phase II VERONA results, including vision improvement and fewer supplemental injections with DURAVYU. The company expects simultaneous top-line results from the two Phase III trials, which enrolled more than 550 patients, in early Q4 2027; efficacy in these pivotal studies remains unproven.
• After the wet AMD results, EyePoint amended DME rescue-injection criteria so patients may receive supplemental treatment after a greater-than-five-letter BCVA decline from baseline alongside a CST increase of at least 50 microns. The company says the change is intended to help preserve vision and protect the trials’ non-inferiority objective; it is not planning a futility analysis.
• EyePoint plans to reduce its workforce by about 53% and says the move will generate approximately $30 million in annualized savings once fully implemented, aligning spending with the DME program.

Eyepoint Pharmaceuticals Stock Down 7.7%

EYPT stock traded down $0.03 during midday trading on Thursday, reaching $0.33. The company’s stock had a trading volume of 4,003,271 shares, compared to its average volume of 3,681,834. Eyepoint Pharmaceuticals has a 52 week low of $0.31 and a 52 week high of $19.11. The stock has a market cap of $28.36 million, a PE ratio of -0.09 and a beta of 1.84. The business’s 50-day simple moving average is $2.50 and its 200-day simple moving average is $10.40.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on EYPT shares. Royal Bank Of Canada reduced their target price on shares of Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating for the company in a research note on Tuesday, October 20th. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. Mizuho downgraded Eyepoint Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $0.50 price objective for the company. in a research report on Tuesday, October 20th. Citigroup decreased their price objective on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Finally, Guggenheim cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $21.85.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.